Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 7/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472436 | 0.85 | NR4A2 (1.00) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472616 | 0.84 | NR4A2 (0.85) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1472510 | 0.82 | NR4A2 (0.56) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472462 | 0.81 | NR4A2 (0.79) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472718 | 0.81 | NR4A2 (0.65) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472629 | 0.80 | NR4A2 (0.73) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472478 | 0.80 | NR4A2 (0.73) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472600 | 0.79 | NR4A2 (0.76) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1474900 | 0.75 | NR4A2 (0.77) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472853 | 0.74 | NR4A2 (0.78) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | claimed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | claimed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | claimed |
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NCOR1, NR4A2, NR4A3 | NR4A2 2/4885KCNH2 2584/4885CYP2C9 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.